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Introduction
To best understand the use of dried blood spots (DBS) in clinical chemistry, we must first 
differentiate laboratory screening from diagnostics. Newborn screening (NBS) utilizes DBS 
to detect and quantify biomarkers indicative of more than 50 congenital diseases primarily 
of metabolic origin [1]. Many different methods are used, including modern analytical 
technologies such as tandem mass spectrometry (MS/MS) [2, 3] and molecular analyses [4, 
5]. Each method is designed specifically to analyze DBS specimens with laboratory 
protocols and systems that begin with a paper hole puncher rather than a pipette. 
Unfortunately, NBS is often differentiated from clinical chemistry because it is “screening” 
tool rather than a “diagnostic” application. This is a common misconception because no 
method is diagnostic, but rather leads to a physician diagnosis that is based, in part, on 
laboratory results. Like any clinical test, NBS results take into consideration additional data 
such as age of newborn, birth weight, gestational age, and nutritional status [6–8]. 
Additionally, NBS is regulated by a comprehensive quality assurance/quality control 
(QA/QC) network that is shared worldwide [9]. There are a small number of traditional 
clinical laboratories that use DBS in a diagnostic setting, primarily in specialized metabolic 
applications, further supporting that DBS utilization is not restricted to “screening” 
laboratories, nor does it involve relaxed laboratory standards. The question is: why are DBS 
not used to a greater extent in traditional clinical laboratories? It is likely due to the 
analytical challenges and common misperceptions of the DBS. Specifically, the challenges 
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of DBS implementation such as cross-validation of a DBS assay from a liquid sample 
analysis, logistical systems limitations for handling DBS versus liquid samples, and clinical 
laboratory bias towards single metabolite analysis versus metabolic profiles.
Advantages of DBS
DBS are whole blood specimens obtained directly from the patient being tested. For 
newborns DBS are collected as a heel stick and in adults, a finger prick. Approximately 
200–300 µL of blood (4–6 drops) is needed for DBS analysis as compared to 5–10 mL of 
blood by venipuncture for most clinical assays. A reduction of blood volume required for 
collection and analysis is the primary advantage of DBS in clinical chemistry, especially for 
newborns and premature infants. Although there are new methods of sample collection that 
utilize small volumes of blood or plasma, a DBS card has the added advantage in that it can 
easily be sampled multiple times for a variety of assays; which is more challenging than in 
any small-volume liquid specimen collection.
One major advantage of DBS versus liquid specimens is shipping and storage requirements 
[10]. DBS can be shipped in a standard business envelope following proper labeling 
requirements, while blood or plasma requires refrigeration or packaging with dry ice which 
can be expensive and often requires overnight shipping. In terms of storage, enzymes are 
inactivated in the dry state, thus enhancing their stability on the DBS matrix and many 
proteins and metabolites have been shown to be stable in DBS [11]. Furthermore, the 
storage space requirements are dramatically reduced, refrigeration is not necessarily 
required, and the potential for infection is less than with liquid specimens. We return to the 
obvious question, why don’t clinical laboratories embrace the DBS specimen? The answer, 
in part, is the perception that sampling issues (volume obtained) of DBS specimens are 
problematic [12–14].
DBS Challenges and Solutions
Most sampling of DBS is done by obtaining a punch (a portion of an entire blood spot) from 
the filter paper specimen collection card and the blood volume in this punch can be 
estimated by the diameter of the punch. Three factors influence the estimated volume from a 
specific diameter punch, filter paper absorptivity, blood volume applied to the paper, and 
hematocrit influences, and must be taken into account for any successful DBS analysis. First 
is the absorptivity of the filter paper, which is controlled by standardization of all paper used 
in NBS [15]. That same standard can be applied to clinical laboratory tests. Second, the 
volume of blood applied to the paper can impact the saturation of the paper. While the exact 
volume of the blood drop applied to filter paper may vary, by printing a target on the filter 
paper (dashed circles) and filling these circles completely can ensure that 50–75 µL whole 
blood is present in each target area. Double-spotting (layering) can also be a problem but is 
usually obvious on inspection. Third, the hematocrit influences the surface area that blood 
will spread for any given volume applied. Hematocrit variations only affect blood volume 
significantly at very high or low values. When blood is collected properly and these 
concerns are addressed, then a DBS specimen is accurate to within 15%. However, 
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quantification and perceived inaccuracies are still partly to blame for the lack of adoption of 
DBS in clinical chemistry outside of NBS.
Solutions to DBS implementation in clinical chemistry begin by understanding the analytical 
approaches used in NBS [16].
Another, less recognized issue in the quantification of metabolites from DBS is the 
efficiency of analyte extraction into a liquid solvent that contains the reference standards 
[17]. With liquid analysis, these standards can be added to the specimen. Errors in the 
extraction process will affect both internal standards and metabolites. In stable-isotope 
dilution mass spectrometry (IDMS) methods, the standard is often an isotopologue and 
behaves like the metabolite measured. In DBS analysis, it is presumed no standard was 
added during the collection process but rather during the extraction or sample preparation. A 
reduction in the extraction of metabolites often occurs if DBS cannot be completely 
reconstituted in a solvent or liquid matrix. This can lead to errors if the extraction efficiency 
(recovery) is not taken into account or is not reproducible.
Newborn screening utilizes DBS exclusively while most clinical chemistry tests use plasma 
obtained from whole blood. To see a significant utilization of DBS in clinical chemistry, 
there would have to be a demonstrable need for its use based on its advantages as described 
here. Furthermore, DBS widespread adoption in the near future is challenging as the existing 
infrastructure in clinical laboratories, especially hospital-based are heavily dependent on 
clinical auto analyzers, which utilize colorimetric assays, as the main tools in the clinical 
laboratory which are not DBS compatible. These systems are highly automated and perform 
many different assays, and have dedicated staff, laboratory technicians trained in their use 
and significant capital invested in them. However, DBS can make inroads into clinical use in 
laboratories that use specialized analytical tools such as gas chromatography/mass 
spectrometry, liquid chromatography/mass spectrometry, and molecular analysis, rather than 
large auto analyzers. Many specialized laboratories have been embracing these technologies 
and will make it easier to introduce DBS analysis rather than whole blood or plasma. The 
use of mass spectrometry-based analyzers in particular enables detection of many 
biomarkers present in blood at very low levels [18–20]; laboratory personnel must be trained 
on DBS sampling and handling after a method has been properly validated.
Cross-validation of DBS with comparison to existing whole blood/plasma-based assays is 
key for its introduction into a clinical laboratory workflow. Analytically it is a challenge to 
compare whole blood versus plasma, thus most assay developments compare plasma to 
DBS. It is important to understand that metabolite levels in blood may be different than in 
plasma and must be considered.
In terms of solving the limitations of DBS such as hematocrit, a focus on more accurately 
measuring the blood volume of the sample obtained would be useful regardless of spot size 
or hematocrit. Delivering known volumes of blood to a DBS card using a calibrated pipette 
will help, provided there was no hemolysis, clotting, or disruption of the paper upon 
spotting. Addition of internal standards during the collection process would all but eliminate 
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extraction efficiency errors in filter paper specimen collection, if mixing could be assured 
and costs kept low.
Some metabolic analyses in liquid are problematic if these metabolites are unstable or 
converted to other metabolites prior to analysis. These issues can often be addressed when 
using DBS [21]. However, if an analysis in a liquid specimen, with high precision (low 
coefficients of variation), is not accurate because of sample degradation, why isn’t the 
alternative solution (DBS) considered? Is accuracy in the measurement better than precision 
when it comes to disease diagnostics? Clinical chemists should weigh the tradeoff between 
accuracy and precision and develop new approaches to interpretation of data such as 
concentration ratios of metabolites [22], detection of multiple markers supporting a disease 
diagnosis [7, 23], and markers that may represent liquid compartments (i.e., extracellular 
fluid, intracellular fluid).
DBS Outlook in Clinical Chemistry
There are many novel solutions that will improve the use of DBS in both screening and 
clinical laboratories [24]. This improvement may be observed when the advantages of DBS 
far outweigh the perceived disadvantages [12]. Clearly this is the case with newborn 
screening and metabolic diagnostic laboratories. Perhaps areas of clinical chemistry such as 
disease and drug monitoring or clinical trials will be where the evidence is obtained for its 
expansion [25]. In both these areas the need for offsite, small volume collection with stable 
storage and biosafety may outweigh any analytical concerns.
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